12:05 PM EDT, 04/29/2020 (MT Newswires) — Capricor Therapeutics (CAPR) has nearly tripled in price on Wednesday, recently climbing 182%, following the US Food and Drug Administration approving expanded testing of its CAP-1002 drug candidate after the company reported new data from a preliminary trial showing a 100% survival rate in critically ill COVID-19 patients treated with the cardiac cell therapy.
Six COVID-19 patients with acute respiratory distress syndrome, including five patients on mechanical ventilators, received intravenous injections of CAP-1002 under compassionate care guidelines over 30 days. All six patients survived, Capricor said, with four of the patients no longer needing ventilator support within four days of their initial treatment and have since been discharged. One of the remaining hospitalized patients is still using a ventilator while the other is receiving supplemental oxygen, it said.
The new trial will enroll up to 20 COVID-19 patients, with the company also planning for a randomized, placebo-controlled trial it expects will be funded by non-equity capital. Capricor also has submitted the initial trial data for publication.
Price: 6.80, Change: +4.39, Percent Change: +182.16